- Home
- CHNR vs MYNZ Comparison
CHNR vs MYNZ Comparison
Compare CHNR & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- MYNZ
- Stock Information
- Founded
- CHNR N/A
- MYNZ 2021
- Country
- CHNR China
- MYNZ Germany
- Employees
- CHNR N/A
- MYNZ N/A
- Industry
- CHNR Precious Metals
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- MYNZ Health Care
- Exchange
- CHNR Nasdaq
- MYNZ Nasdaq
- Market Cap
- CHNR 4.6M
- MYNZ 5.5M
- IPO Year
- CHNR 1995
- MYNZ 2021
- Fundamental
- Price
- CHNR $3.41
- MYNZ $1.49
- Analyst Decision
- CHNR
- MYNZ Buy
- Analyst Count
- CHNR 0
- MYNZ 2
- Target Price
- CHNR N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CHNR 153.2K
- MYNZ 120.2K
- Earning Date
- CHNR 05-15-2025
- MYNZ 07-15-2025
- Dividend Yield
- CHNR N/A
- MYNZ N/A
- EPS Growth
- CHNR N/A
- MYNZ N/A
- EPS
- CHNR N/A
- MYNZ N/A
- Revenue
- CHNR N/A
- MYNZ $893,991.00
- Revenue This Year
- CHNR N/A
- MYNZ $26.06
- Revenue Next Year
- CHNR N/A
- MYNZ $4.97
- P/E Ratio
- CHNR N/A
- MYNZ N/A
- Revenue Growth
- CHNR N/A
- MYNZ N/A
- 52 Week Low
- CHNR $3.35
- MYNZ $1.34
- 52 Week High
- CHNR $9.04
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- CHNR 37.29
- MYNZ 35.61
- Support Level
- CHNR $3.35
- MYNZ $1.35
- Resistance Level
- CHNR $3.71
- MYNZ $1.46
- Average True Range (ATR)
- CHNR 0.29
- MYNZ 0.09
- MACD
- CHNR -0.06
- MYNZ 0.04
- Stochastic Oscillator
- CHNR 5.04
- MYNZ 62.93
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.